Evaluation for other causes of anemia in patients being considered for an erythropoiesis-stimulating agent

Thorough drug exposure history

Review of a peripheral blood smear and, in some cases, bone marrow examination

Analysis for iron, total iron binding capacity, transferrin saturation, ferritin, folate, vitamin B12, or hemoglobinopathy screening (where indicated)

Assessment of reticulocyte count, occult blood loss, and renal insufficiency

Baseline erythropoietin level

Testing of serum thyroid-stimulating hormone level (where indicated)

Investigations may also include direct antiglobulin testing (eg, Coombs test) for patients with chronic lymphocytic leukemia, non-Hodgkin lymphoma, or a history of autoimmune disease

Adapted from: Bohlius J, Bohlke K, Castelli R, et al. Management of Cancer-Associated Anemia With Erythropoiesis-Stimulating Agents: ASCO/ASH Clinical Practice Guideline Update. J Clin Oncol 2019. Reprinted with permission. Copyright © 2019 American Society of Clinical Oncology. All rights reserved.

Graphic 60121 Version 5.0

خرید پکیج

Evaluation for other causes of anemia in patients being considered for an erythropoiesis-stimulating agent